Hoth Therapeutics Unveils Promising HT-001 Data for Cancer Patients with Skin Toxicities

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has recently shared significant advancements regarding its investigational treatment, HT-001, which primarily targets cancer patients experiencing skin toxicities due to Epidermal Growth Factor Receptor (EGFR) therapies. The latest results outline remarkable pharmacokinetic (PK) findings and a favorable safety profile, presenting hope for patients dealing with discomfort from these adverse effects.

The Company reported a roughly 77% increase in systemic drug exposure following repeated dosing of HT-001. This substantial boost in drug exposure is complemented by minimal systemic absorption, a crucial element in enhancing treatment effectiveness while minimizing side effects. Specifically, HT-001 demonstrated a significant reduction in systemic levels compared to conventional oral formulations approved by the FDA.

Clinical data reveal striking improvements in patient outcomes. Notably, subjects using HT-001 exhibited not only reductions in symptom severity but also sustained therapeutic responses throughout their treatment period. These results have generated optimism that enhanced drug exposure correlates with more favorable clinical responses among treated individuals.

In a detailed pharmacokinetic assessment, it was noted that the mean Area Under the Curve (AUC₀–₂₄) increased significantly over the treatment period, rising from 45.61 h•ng/mL on Day 1 to 80.60 h•ng/mL on Day 42—indicating a marked increase in systemic exposure of nearly 76.7%. Additional metrics, including mean Cavg and Cmax, also showed consistent increases, thereby confirming the drug's efficacy likely aligns with its pharmacokinetic profile.

One of the critical points of emphasis is the remarkably low systemic exposure observed with the topical formulation of HT-001. On Day 1, this exposure was merely 0.2% of what is typically seen with oral EGFR inhibitors. This percentage remained low throughout the study, particularly on Day 42, reflecting a systemic absorption rate that did not exceed 0.5% despite prolonged use. Such low absorption figures underscore the potential for a safer alternative treatment that minimizes systemic toxicity.

Safety observations during the trials were highly encouraging. No serious adverse events occurred, which suggests a robust tolerability profile. Moreover, there were no instances of dose-limiting toxicities or discontinuations from treatment, enhancing the confidence in pursuing further clinical developments of HT-001.

Robb Knie, CEO of Hoth Therapeutics, expressed enthusiasm regarding the promising results, stating, “These pharmacokinetic results, coupled with a favorable safety and tolerability profile, bolster our commitment to advancing HT-001. The observed increase in systemic exposure, along with sustained accumulation and minimal systemic absorption, reinforces our strategic approach toward dosing as we continue our development efforts.”

Hoth Therapeutics maintains that these findings strongly support the ongoing clinical advancement and optimization of HT-001’s dosing regimen, especially given the positive correlation observed between pharmacokinetic profiling and symptom reduction.

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical firm committed to developing innovative therapies aimed at improving the overall quality of life for patients. Through a patient-centric approach to drug research and development, Hoth partners with scientific and clinical leaders to investigate groundbreaking treatment options. The Company aims to enhance drugs from the early-stage process through to successful clinical trials. For more information about Hoth Therapeutics, please visit their website.